I just looked back at the original Ph1 safety announcement for...

I just looked back at the original Ph1 safety announcement for HerVax.

Click here

Was from Feb 2018, at the time the shareprice had been 1.3c , over the next few days there were the highest volumes seen in two years, 86 million on the day of announcement, 156 million a few days later, coming off average daily volumes of 5million. 6 weeks later sp made a new high of 3.9c, up 200%

Clearly this can be seen as a major turning point or moment of significant de risking for HerVaxx

Imugene Chief Scientific Officer Professor Dr. Ursula Wiedermann said, “We are pleased that there were no safety issues reported from the Cohort Review Committee. The early clinical data is also encouraging, indicating immune activation in vaccinated patients in a manner that is consistent with the vaccine’s postulated mechanism of action.”

Imugene Chief Executive Officer Leslie Chong said, “We are pleased with the results that we have seen so far. There is no observed toxicity and observing strong immune responses is exciting. Everyone supporting the study and involved in developing this important new cancer therapy are very encouraged by the progress to date.

We are now just days away from the PD1 Vaxx first Cohort review committee on safety / dose escalation.
Be prepared for a similar turning point, this time for a Vaccine that takes on US$20 billion per year in sales... two to three times bigger than Herceptin.

Lets hope we see a very similar worded announcement for PD1 Vaxx.


Chart from 2018 HerVax safety announcement